Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting

Ching L. Tseng, Tzu W. Wang, Guo Chung Dong, Steven Yueh-Hsiu Wu, Tai Horng Young, Ming Jium Shieh, Pei J. Lou, Feng Huei Lin

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Since lung cancer is the most malignant cancer today, a specific drug-delivery system has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) employed as native carriers were grafted with NeutrAvidinFITC on the particle's surface (GP-Av). Next, the biotinylated epithelial growth factor (EGF) molecules were conjugated with NeutrAvidinFITC, forming a core-shell-like structure (GP-Av-bEGF) to achieve the enhancement of targeting efficiency. These nanoparticles were applied as an EGF receptor (EGFR)-seeking agent to detect lung adenocarcinoma. The results showed that the modification process had no significant influence on particle size (220 nm) and zeta potential (-9.3 mV). By the in vitro cell culture test, GP-Av-bEGF resulted in higher entrance efficiency on adenocarcinoma cells (A549) than that on normal lung cells (HFL1) because A549 possessed greater amounts of EGFR. We also found that uptake of GP-Av-bEGF by A549 cells was time and dose dependent. Confocal microscopy confirmed the cellular internalization of GP-Av-bEGF, and more fluorescent spots of GP-Av-bEGF nanoparticles were obviously observed as well as lysosomal entrapment in A549. Finally, the delivery was demonstrated by in vivo aerosol administration to cancerous lung of the SCID mice model, and specific accumulation in cancerous lung was confirmed by image quantification. The targeting ability of GP-Av-bEGF was proved in vitro and in vivo, which holds promise for further anti-cancer drug applications.

Original languageEnglish
Pages (from-to)3996-4005
Number of pages10
JournalBiomaterials
Volume28
Issue number27
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Gelatin
Nanoparticles
Lung Neoplasms
Intercellular Signaling Peptides and Proteins
Lung
SCID Mice
Growth Factor Receptors
Confocal microscopy
Zeta potential
Drug Delivery Systems
Aerosols
Cell culture
Particle Size
Epidermal Growth Factor Receptor
Confocal Microscopy
Neoplasms
Adenocarcinoma
Cell Culture Techniques
Particle size
Molecules

Keywords

  • Drug delivery
  • Gelatin
  • Lung
  • Nanoparticle
  • Surface modification

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Tseng, C. L., Wang, T. W., Dong, G. C., Yueh-Hsiu Wu, S., Young, T. H., Shieh, M. J., ... Lin, F. H. (2007). Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials, 28(27), 3996-4005. https://doi.org/10.1016/j.biomaterials.2007.05.006

Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. / Tseng, Ching L.; Wang, Tzu W.; Dong, Guo Chung; Yueh-Hsiu Wu, Steven; Young, Tai Horng; Shieh, Ming Jium; Lou, Pei J.; Lin, Feng Huei.

In: Biomaterials, Vol. 28, No. 27, 09.2007, p. 3996-4005.

Research output: Contribution to journalArticle

Tseng, CL, Wang, TW, Dong, GC, Yueh-Hsiu Wu, S, Young, TH, Shieh, MJ, Lou, PJ & Lin, FH 2007, 'Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting', Biomaterials, vol. 28, no. 27, pp. 3996-4005. https://doi.org/10.1016/j.biomaterials.2007.05.006
Tseng, Ching L. ; Wang, Tzu W. ; Dong, Guo Chung ; Yueh-Hsiu Wu, Steven ; Young, Tai Horng ; Shieh, Ming Jium ; Lou, Pei J. ; Lin, Feng Huei. / Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. In: Biomaterials. 2007 ; Vol. 28, No. 27. pp. 3996-4005.
@article{b86b1047f4f84fada80f1424f7e0570f,
title = "Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting",
abstract = "Since lung cancer is the most malignant cancer today, a specific drug-delivery system has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) employed as native carriers were grafted with NeutrAvidinFITC on the particle's surface (GP-Av). Next, the biotinylated epithelial growth factor (EGF) molecules were conjugated with NeutrAvidinFITC, forming a core-shell-like structure (GP-Av-bEGF) to achieve the enhancement of targeting efficiency. These nanoparticles were applied as an EGF receptor (EGFR)-seeking agent to detect lung adenocarcinoma. The results showed that the modification process had no significant influence on particle size (220 nm) and zeta potential (-9.3 mV). By the in vitro cell culture test, GP-Av-bEGF resulted in higher entrance efficiency on adenocarcinoma cells (A549) than that on normal lung cells (HFL1) because A549 possessed greater amounts of EGFR. We also found that uptake of GP-Av-bEGF by A549 cells was time and dose dependent. Confocal microscopy confirmed the cellular internalization of GP-Av-bEGF, and more fluorescent spots of GP-Av-bEGF nanoparticles were obviously observed as well as lysosomal entrapment in A549. Finally, the delivery was demonstrated by in vivo aerosol administration to cancerous lung of the SCID mice model, and specific accumulation in cancerous lung was confirmed by image quantification. The targeting ability of GP-Av-bEGF was proved in vitro and in vivo, which holds promise for further anti-cancer drug applications.",
keywords = "Drug delivery, Gelatin, Lung, Nanoparticle, Surface modification",
author = "Tseng, {Ching L.} and Wang, {Tzu W.} and Dong, {Guo Chung} and {Yueh-Hsiu Wu}, Steven and Young, {Tai Horng} and Shieh, {Ming Jium} and Lou, {Pei J.} and Lin, {Feng Huei}",
year = "2007",
month = "9",
doi = "10.1016/j.biomaterials.2007.05.006",
language = "English",
volume = "28",
pages = "3996--4005",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "27",

}

TY - JOUR

T1 - Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting

AU - Tseng, Ching L.

AU - Wang, Tzu W.

AU - Dong, Guo Chung

AU - Yueh-Hsiu Wu, Steven

AU - Young, Tai Horng

AU - Shieh, Ming Jium

AU - Lou, Pei J.

AU - Lin, Feng Huei

PY - 2007/9

Y1 - 2007/9

N2 - Since lung cancer is the most malignant cancer today, a specific drug-delivery system has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) employed as native carriers were grafted with NeutrAvidinFITC on the particle's surface (GP-Av). Next, the biotinylated epithelial growth factor (EGF) molecules were conjugated with NeutrAvidinFITC, forming a core-shell-like structure (GP-Av-bEGF) to achieve the enhancement of targeting efficiency. These nanoparticles were applied as an EGF receptor (EGFR)-seeking agent to detect lung adenocarcinoma. The results showed that the modification process had no significant influence on particle size (220 nm) and zeta potential (-9.3 mV). By the in vitro cell culture test, GP-Av-bEGF resulted in higher entrance efficiency on adenocarcinoma cells (A549) than that on normal lung cells (HFL1) because A549 possessed greater amounts of EGFR. We also found that uptake of GP-Av-bEGF by A549 cells was time and dose dependent. Confocal microscopy confirmed the cellular internalization of GP-Av-bEGF, and more fluorescent spots of GP-Av-bEGF nanoparticles were obviously observed as well as lysosomal entrapment in A549. Finally, the delivery was demonstrated by in vivo aerosol administration to cancerous lung of the SCID mice model, and specific accumulation in cancerous lung was confirmed by image quantification. The targeting ability of GP-Av-bEGF was proved in vitro and in vivo, which holds promise for further anti-cancer drug applications.

AB - Since lung cancer is the most malignant cancer today, a specific drug-delivery system has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) employed as native carriers were grafted with NeutrAvidinFITC on the particle's surface (GP-Av). Next, the biotinylated epithelial growth factor (EGF) molecules were conjugated with NeutrAvidinFITC, forming a core-shell-like structure (GP-Av-bEGF) to achieve the enhancement of targeting efficiency. These nanoparticles were applied as an EGF receptor (EGFR)-seeking agent to detect lung adenocarcinoma. The results showed that the modification process had no significant influence on particle size (220 nm) and zeta potential (-9.3 mV). By the in vitro cell culture test, GP-Av-bEGF resulted in higher entrance efficiency on adenocarcinoma cells (A549) than that on normal lung cells (HFL1) because A549 possessed greater amounts of EGFR. We also found that uptake of GP-Av-bEGF by A549 cells was time and dose dependent. Confocal microscopy confirmed the cellular internalization of GP-Av-bEGF, and more fluorescent spots of GP-Av-bEGF nanoparticles were obviously observed as well as lysosomal entrapment in A549. Finally, the delivery was demonstrated by in vivo aerosol administration to cancerous lung of the SCID mice model, and specific accumulation in cancerous lung was confirmed by image quantification. The targeting ability of GP-Av-bEGF was proved in vitro and in vivo, which holds promise for further anti-cancer drug applications.

KW - Drug delivery

KW - Gelatin

KW - Lung

KW - Nanoparticle

KW - Surface modification

UR - http://www.scopus.com/inward/record.url?scp=34447280627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447280627&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.05.006

DO - 10.1016/j.biomaterials.2007.05.006

M3 - Article

VL - 28

SP - 3996

EP - 4005

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 27

ER -